Regeneron’s Veopoz Receives FDA Go-Ahead
Medicine designated for the treatment of children and adults with chaple disease.
Regeneron Pharmaceuticals has confirmed the FDA approval of Veopoz (pozelimab-bbfg), designated for adult and pediatric patients one year of age and older with chaple disease, also known as CD55-deficient protein-losing enteropathy. According to a company press release, the treatment is the first and only one indicated for the potentially life-threatening gastrointestinal and cardiovascular disease.
“As the first-ever treatment for chape, Veopoz is a testament to our commitment to uncovering genetic insights and applying them to the development of effective treatments for patients in need – regardless of the prevalence of their disease,” said George D. Yancopoulos, MD, PhD, board co-chair, president, chief scientific officer, Regeneron, as per the release. “Beyond chaple, we believe Veopoz has promise in a variety of complement-mediated diseases and are driving forward several clinical programs to explore its broader potential.”
Reference: VEOPOZ™ (POZELIMAB-BBFG) RECEIVES FDA APPROVAL AS THE FIRST TREATMENT FOR CHILDREN AND ADULTS WITH CHAPLE DISEASE. Regeneron. August 18, 2023. Accessed August 21, 2023.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
